FR16C0004I1 - Composes cepheme - Google Patents

Composes cepheme

Info

Publication number
FR16C0004I1
FR16C0004I1 FR16C0004C FR16C0004I1 FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1 FR 16C0004 C FR16C0004 C FR 16C0004C FR 16C0004 I1 FR16C0004 I1 FR 16C0004I1
Authority
FR
France
Prior art keywords
cephem compounds
cephem
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR16C0004I1 publication Critical patent/FR16C0004I1/fr
Application granted granted Critical
Publication of FR16C0004I2 publication Critical patent/FR16C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR16C0004C 2002-10-30 2016-02-03 Composes cepheme Active FR16C0004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (fr) 2002-10-30 2003-10-27 Composes cepheme

Publications (2)

Publication Number Publication Date
FR16C0004I1 true FR16C0004I1 (fr) 2016-03-25
FR16C0004I2 FR16C0004I2 (fr) 2017-01-06

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0004C Active FR16C0004I2 (fr) 2002-10-30 2016-02-03 Composes cepheme

Country Status (20)

Country Link
US (2) US7129232B2 (fr)
EP (1) EP1556389B9 (fr)
JP (1) JP4448821B2 (fr)
KR (1) KR101023035B1 (fr)
AR (1) AR041729A1 (fr)
AT (1) ATE368042T1 (fr)
BE (1) BE2016C002I2 (fr)
BR (1) BRPI0315188B8 (fr)
CA (1) CA2504730C (fr)
DE (1) DE60315178T3 (fr)
DK (1) DK1556389T6 (fr)
ES (1) ES2290498T7 (fr)
FR (1) FR16C0004I2 (fr)
HK (1) HK1086566A1 (fr)
HU (1) HUS1600008I1 (fr)
LU (1) LU92943I2 (fr)
NL (1) NL300793I2 (fr)
PT (1) PT1556389E (fr)
TW (1) TWI319403B (fr)
WO (1) WO2004039814A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254671T3 (es) * 2001-05-01 2006-06-16 Astellas Pharma Inc. Compuestos de cefem.
DK1556389T6 (da) * 2002-10-30 2015-05-11 Astellas Pharma Inc Cephemforbindelser
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
MXPA06003068A (es) 2003-09-18 2006-08-25 Astellas Pharma Inc Compuestos de cefem.
WO2005063704A1 (fr) * 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. Composes cycliques d'azetidine et medicaments les renfermant
EP1994035A1 (fr) * 2006-03-16 2008-11-26 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
JP5733856B2 (ja) 2007-10-09 2015-06-10 ソファーミア，インコーポレイテッド 広帯域β−ラクタマーゼ阻害薬
MX347952B (es) 2011-05-13 2017-05-19 Array Biopharma Inc Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka.
EP2862569A1 (fr) 2011-09-09 2015-04-22 Cubist Pharmaceuticals, Inc. Procédés pour traiter des infections intrapulmonaires
EP2628730B1 (fr) * 2012-02-16 2017-12-06 Noxell Corporation Synthèse télescopique des sels de 5-amino-4-nitroso-1-alkyl-1h-pyrazole
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
KR102143256B1 (ko) 2012-09-27 2020-08-11 머크 샤프 앤드 돔 코포레이션 타조박탐 아르기닌 항생물질 조성물
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9006421B2 (en) 2013-03-14 2015-04-14 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP2893929A1 (fr) 2013-03-15 2015-07-15 Cubist Pharmaceuticals, Inc. Compositions antibiotiques à base de ceftolozane
WO2015035376A2 (fr) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Traitement d'infections au moyen de ceftolozane/tazobactam chez des sujets ayant une fonction rénale altérée
US20150094293A1 (en) * 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US10835533B2 (en) 2014-05-15 2020-11-17 Array Biopharma Inc. 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor
WO2016025813A1 (fr) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Intermédiaires dans la synthèse de composés de céphalosporine
EP3180347B1 (fr) 2014-08-15 2020-09-23 Merck Sharp & Dohme Corp. Synthèse de composés de céphalosporine
WO2016028670A1 (fr) * 2014-08-18 2016-02-25 Merck Sharp & Dohme Corp. Formes salines de ceftolozane
WO2016100897A1 (fr) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Composés dérivés de l'acide thiadiazolyl-oxyminoacétique
US10035774B2 (en) 2014-12-18 2018-07-31 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
WO2016109259A2 (fr) * 2014-12-30 2016-07-07 Merck Sharp & Dohme Corp. Synthèse de composés de céphalosporine
EP3313821B1 (fr) * 2015-06-29 2019-04-10 Sandoz AG Procédé de préparation de dérivés de pyrazole carbamoylamino
EP3347362B1 (fr) 2015-09-08 2019-10-23 Sandoz AG Procédé pour la préparation de ceftolozane a partir du acide 7-aminocéphalosporanique (7-aca)
CN108463461B (zh) 2015-12-10 2021-11-19 奈加-Rgm制药有限公司 头孢烯化合物、其制备和用途
US11542279B2 (en) 2016-06-06 2023-01-03 Merck Sharp & Dohme Llc Solid forms of ceftolozane and processes for preparing
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (fr) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Polythérapies pour agents pathogènes résistant aux médicaments multiples
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (fr) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (fr) * 1986-09-22 1991-12-31 Takao Takaya Composes de cephem et procede de preparation
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
ES2254671T3 (es) * 2001-05-01 2006-06-16 Astellas Pharma Inc. Compuestos de cefem.
DK1556389T6 (da) * 2002-10-30 2015-05-11 Astellas Pharma Inc Cephemforbindelser
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
MXPA06003068A (es) * 2003-09-18 2006-08-25 Astellas Pharma Inc Compuestos de cefem.

Also Published As

Publication number Publication date
PT1556389E (pt) 2007-11-08
NL300793I1 (fr) 2016-03-15
ATE368042T1 (de) 2007-08-15
HUS1600008I1 (hu) 2016-03-29
EP1556389B3 (fr) 2015-04-01
KR101023035B1 (ko) 2011-03-24
DK1556389T3 (da) 2007-11-26
ES2290498T7 (es) 2015-07-10
US20040132994A1 (en) 2004-07-08
HK1086566A1 (en) 2006-09-22
BRPI0315188B8 (pt) 2021-05-25
DE60315178D1 (de) 2007-09-06
EP1556389A1 (fr) 2005-07-27
ES2290498T3 (es) 2008-02-16
DK1556389T6 (da) 2015-05-11
EP1556389B9 (fr) 2015-09-09
NL300793I2 (fr) 2016-03-15
BR0315188A (pt) 2005-09-06
BRPI0315188B1 (pt) 2017-04-25
FR16C0004I2 (fr) 2017-01-06
DE60315178T3 (de) 2015-06-18
BE2016C002I2 (fr) 2023-03-07
LU92943I2 (fr) 2016-03-14
TWI319403B (en) 2010-01-11
US7129232B2 (en) 2006-10-31
CA2504730C (fr) 2011-04-12
JP4448821B2 (ja) 2010-04-14
US20070037786A1 (en) 2007-02-15
WO2004039814A1 (fr) 2004-05-13
DE60315178T2 (de) 2008-04-30
KR20050084897A (ko) 2005-08-29
AR041729A1 (es) 2005-05-26
EP1556389B1 (fr) 2007-07-25
CA2504730A1 (fr) 2004-05-13
TW200410977A (en) 2004-07-01
JP2006506459A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
FR16C0004I2 (fr) Composes cepheme
MA27105A1 (fr) Nouveaux composes
DE60312848D1 (de) Verbindungsanschluss
NO20044046L (no) Substituerte hydroksyetylaminer
IS7381A (is) Efnasambönd
DE60326590D1 (de) Tend lamotrigin
ATE463248T1 (de) Cephem-verbindungen
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
NO20031114D0 (no) Signallys
ATE318269T1 (de) Cephem-verbindungen
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
NO20034147L (no) Trykkfoleranordning
ATA4142004A (de) Trägerverbau
FR2839740B3 (fr) Bourrelet perfectionne
ATE350379T1 (de) Substituierte benzdioxepine
DE50303658D1 (de) Postgutmessvorrichtung
DE60305506D1 (de) Cephalosporine
AT5889U3 (de) Brennholzspleisser
AU2003274754A8 (en) Cephem compounds
DE50207561D1 (de) Gurthöhenverstellteil
DE50311554D1 (de) Filterhalter
SE0200908D0 (sv) Signal
DE60311693D1 (de) Klassiermünzbehälter
DE60207974D1 (de) Cyclohexenylcyclopropylketon